Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.56 |
| ▸ | CCR2 | P41597 | 2/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696251 | 0.90 | AKR1C3 (0.67) | AKR1C3AKR1C2CCR2AKR1C1APP | |
| SCHEMBL8747120 | 0.87 | AKR1C3 (0.60) | AKR1C3AKR1C2CCR2AKR1C1APP | |
| SCHEMBL3116411 | 0.87 | AKR1C3 (0.60) | AKR1C3AKR1C2CCR2AKR1C1APP | |
| SCHEMBL3138704 | 0.83 | AKR1C3 (0.56) | AKR1C3AKR1C2CCR2AKR1C1APP | |
| SCHEMBL1626229 | 0.82 | APP (0.55) | AKR1C3AKR1C2AKR1C1APPALDH1A1 | |
| SCHEMBL1626768 | 0.81 | ALDH1A1 (0.48) | AKR1C3AKR1C2AKR1C1APPHCAR2 | |
| SCHEMBL5726893 | 0.81 | AKR1C3 (0.54) | AKR1C3AKR1C2CCR2AKR1C1APP | |
| SCHEMBL23164271 | 0.79 | GRIN1 (0.48) | AKR1C3AKR1C2APPALDH1A1 | |
| SCHEMBL1627580 | 0.78 | AKR1C1 (0.68) | AKR1C1ALDH1A1 | |
| SCHEMBL1627025 | 0.78 | MEN1 (0.50) | AKR1C3AKR1C2CCR2AKR1C1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642782-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | Pliant Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2111399-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008076427-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | AKR1C3 382/4885AKR1C2 272/4885CCR2 4135/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | AKR1C3 382/4885AKR1C2 272/4885CCR2 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.